HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.04.086v1 48/5/914    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (17) Citing Articles via Google Scholar Google Scholar Articles by Kaul, S. Articles by Shah, P. K. Search for Related Content PubMed PubMed Citation Articles by Kaul, S. Articles by Shah, P. K.

STATE-OF-THE-ART PAPER

Homocysteine Hypothesis for Atherothrombotic Cardiovascular Disease

Not Validated

Sanjay Kaul, MD^_*,,1,_*, Andrew A. Zadeh, MD^_*,,1 and Prediman K. Shah, MD^_*,

^_* Division of Cardiology, Cedars-Sinai Medical Center, University of California, Los Angeles, California.
David Geffen School of Medicine, University of California, Los Angeles, California.

Manuscript received January 24, 2006; revised manuscript received March 28, 2006, accepted April 4, 2006.

^_* Reprint requests and correspondence: Dr. Sanjay Kaul, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048. (Email: kaul{at}cshs.org).

Homocysteine has been implicated in promoting atherosclerotic and thrombotic vascular disease. During the last decade, the utility of homocysteine in predicting risk for atherothrombotic vascular disease has been evaluated in several observational studies in a large number of patients. These studies show that the overall risk for vascular disease is small, with prospective, longitudinal studies reporting a weaker association between homocysteine and atherothrombotic vascular disease compared to retrospective case-control and cross-sectional studies. Furthermore, randomized controlled trials of homocysteine-lowering therapy have failed to prove a causal relationship. On the basis of these results, there is currently insufficient evidence to recommend routine screening and treatment of elevated homocysteine concentrations with folic acid and other vitamins to prevent atherothrombotic vascular disease. This review outlines the metabolism and pathophysiology of homocysteine, highlights the results of homocysteine observational and interventional trials, and presents areas of uncertainty and potential future work.

Abbreviations and Acronyms   CAD = coronary artery disease   CVD = cardiovascular disease   HOPE-2 = Heart Outcomes Prevention Evaluation-2 trial   IHD = ischemic heart disease   MACE = major adverse cardiac event   MI = myocardial infarction   MTHFR = methylene tetrahydrofolate reductase   NORVIT = Norwegian Vitamin Trial   tHcy = total homocysteine   VISP = Vitamin Intervention for Stroke Prevention study

This article has been cited by other articles:

				G. S. Getz and C. A. Reardon Nutrition and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2499 - 2506. [Abstract] [Full Text] [PDF]

				S. Kaul, A. A. Zadeh, and P. K. Shah Reply J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1371 - 1371. [Full Text] [PDF]

				N. Akhtar Is Homocysteine a Risk Factor for Atherothrombotic Cardiovascular Disease? J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1370 - 1371. [Full Text] [PDF]

				K. M. Wilson, R. B. McCaw, L. Leo, E. Arning, S. Lhotak, T. Bottiglieri, R. C. Austin, and S. R. Lentz Prothrombotic Effects of Hyperhomocysteinemia and Hypercholesterolemia in ApoE-Deficient Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 233 - 240. [Abstract] [Full Text] [PDF]